+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Spinal Muscular Atrophy Treatment Market by Treatment Type, Patient Type, Route of Administration, End User, Distribution Channel - Global Forecast to 2030- Product Image
Spinal Muscular Atrophy Treatment Market by Treatment Type, Patient Type, Route of Administration, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Spinal Muscular Atrophy Treatment Market by Treatment Type, Patient Type, Route of Administration, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012079
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Spinal Muscular Atrophy Treatment Market is rapidly evolving, driven by scientific innovation, changing regulatory approaches, and heightened focus on patient outcomes. Senior leadership in healthcare and life sciences needs a clear, actionable analysis that goes beyond headline numbers to inform strategic decision-making in this dynamic therapeutic area.

Market Snapshot: Spinal Muscular Atrophy Treatment Market

The global Spinal Muscular Atrophy Treatment Market grew from USD 1.85 billion in 2024 to USD 2.15 billion in 2025 and is projected to continue expanding at a compound annual growth rate of 15.44%, reaching USD 4.38 billion by 2030. Growth reflects rapid adoption of gene-based and targeted treatments, alongside expanded access initiatives in established and emerging regions.

Scope & Comprehensive Segmentation

  • Treatment Types: Gene therapy, SMN2-targeted therapy, and supportive therapy address a spectrum of disease pathways and therapeutic goals.
  • Patient Types: SMA manifests across four types, from infantile onset cases requiring urgent intervention, to adult-stage disease with varying management needs.
  • Route of Administration: Modalities include intrathecal, intravenous, and emerging oral treatments, each impacting delivery complexity and access.
  • End User Settings: Distribution encompasses homecare, hospitals, and specialty clinics, allowing tailored patient management and resource allocation.
  • Distribution Channels: Hospital pharmacies, online pharmacies, and specialty pharmacies each play a vital role in therapy access and reimbursement support.
  • Geographic Coverage: Americas (including United States, Canada, Mexico, Brazil, Argentina); Europe, Middle East, Africa (with prominent and emerging markets), and Asia-Pacific (notably Japan, South Korea, Australia, Southeast Asian nations).
  • Key Market Players: Biogen Inc., Novartis AG, Roche Holding AG, Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc. lead innovation, partnerships, and regional presence.

Key Takeaways for Decision-Makers

  • Gene therapy acts as a paradigm shift, offering potential for a one-time intervention targeting the underlying genetic cause and changing long-term patient outlooks.
  • SMN2-targeted therapies, including advanced antisense approaches, provide functional improvements across diverse patient populations, supporting earlier and more sustained intervention.
  • Enhanced supportive care, multidisciplinary teams, and digital health tools are redefining the patient journey, increasing accessibility, and aligning outcomes with stakeholder expectations.
  • The emergence of innovative financing, such as outcomes-based and annuity payment models, addresses affordability concerns and aligns stakeholder incentives with treatment success.
  • Competitive dynamics are shaped by both established biopharma organizations and agile biotech firms, fueling robust pipelines and cross-sector partnerships.
  • Market access initiatives, such as newborn screening programs and regional harmonization efforts, are expected to accelerate identification and optimize therapeutic pathways globally.

Tariff Impact: Navigating U.S. 2025 Changes

Revised United States tariffs scheduled for 2025 introduce new supply chain and cost management complexities for the sector. Companies with integrated manufacturing may experience greater resilience, but those dependent on external suppliers could see margin pressure. Industry responses include evaluating domestic production capacity, adopting agile partnerships, and implementing performance-linked pricing approaches. Pricing strategies are shifting toward value-based contracting and innovative reimbursement, aiming to sustain patient access amid changing cost structures.

Methodology & Data Sources

This analysis combines primary research—interviews with neurologists, geneticists, payers, and advocacy leaders—with a thorough review of secondary sources, including regulatory filings and industry publications. Rigorous data validation and triangulation ensure credible directional trends and minimize reliance on projections. Segmentation is informed by epidemiological data, treatment uptake, and care-setting prevalence.

Why This Report Matters

  • Enables executive teams to navigate complex regulatory, pricing, and market-access environments with up-to-date market intelligence.
  • Supports investment decisions by highlighting high-impact therapeutic innovations, key regional opportunities, and evolving payer expectations.
  • Facilitates strategic planning for pipeline management, cross-functional partnerships, and deployment of digital solutions to maximize patient engagement and clinical outcomes.

Conclusion

The SMA treatment landscape reflects a convergence of robust scientific advances, collaborative care models, and adaptive commercial strategies. Market leaders who leverage these insights will be positioned to shape patient access and long-term therapeutic success in the evolving landscape of neuromuscular care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Spinal Muscular Atrophy Treatment Market, by Treatment Type
8.1. Introduction
8.2. Gene Therapy
8.3. SMN2-Targeted Therapy
8.4. Supportive Therapy
9. Spinal Muscular Atrophy Treatment Market, by Patient Type
9.1. Introduction
9.2. Type I
9.3. Type II
9.4. Type III
9.5. Type IV
10. Spinal Muscular Atrophy Treatment Market, by Route of Administration
10.1. Introduction
10.2. Intrathecal
10.3. Intravenous
10.4. Oral
11. Spinal Muscular Atrophy Treatment Market, by End User
11.1. Introduction
11.2. Homecare Settings
11.3. Hospitals
11.4. Specialty Clinics
12. Spinal Muscular Atrophy Treatment Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Specialty Pharmacy
13. Americas Spinal Muscular Atrophy Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Spinal Muscular Atrophy Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Spinal Muscular Atrophy Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Biogen Inc.
16.3.2. Novartis AG
16.3.3. Roche Holding AG
16.3.4. Ionis Pharmaceuticals, Inc.
16.3.5. PTC Therapeutics, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. SPINAL MUSCULAR ATROPHY TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. SPINAL MUSCULAR ATROPHY TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. SPINAL MUSCULAR ATROPHY TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SMN2-TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE IV, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 39. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 40. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 41. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 45. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 46. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 61. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 66. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 67. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 71. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 72. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 76. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 77. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 81. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 82. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 86. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 87. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 91. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 92. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 96. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 97. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 101. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 102. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 106. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 111. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 112. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 116. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 117. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 122. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 126. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 127. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 136. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 137. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 141. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 142. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 146. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 151. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 152. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 156. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 157. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 161. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 162. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 166. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 167. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 176. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 177. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 178. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 183. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 187. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 188. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 197. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 198. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 202. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 203. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 207. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 208. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 212. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 213. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 217. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 222. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 223. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 227. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 228. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 232. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 233. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
TABLE 237. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Spinal Muscular Atrophy Treatment market report include:
  • Biogen Inc.
  • Novartis AG
  • Roche Holding AG
  • Ionis Pharmaceuticals, Inc.
  • PTC Therapeutics, Inc.

Table Information

Report AttributeDetails
No. of Pages194
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.15 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.38 Billion
Compound Annual Growth Rate15.4%
Regions CoveredGlobal
No. of Companies Mentioned6

Related Topics

Related Reports

Drugs for Spinal Muscular Atrophy Market by Product Type, Treatment Type, Distribution Channel, Patient Age Group - Global Forecast to 2030 - Product Image

Drugs for Spinal Muscular Atrophy Market by Product Type, Treatment Type, Distribution Channel, Patient Age Group - Global Forecast to 2030

  • Report
  • 182 Pages
  • Global
From
Spinal Muscular Atrophy Treatment Market Size, Share & Trends Analysis Report By Type, By Treatment, By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Spinal Muscular Atrophy Treatment Market Size, Share & Trends Analysis Report By Type, By Treatment, By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Spinal Muscular Atrophy Treatment Market Report and Forecast 2025-2034 - Product Image

Spinal Muscular Atrophy Treatment Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Spinal Muscular Atrophy - Global Strategic Business Report - Product Image

Spinal Muscular Atrophy - Global Strategic Business Report

  • Report
  • 189 Pages
  • Global
From
Spinal Muscular Atrophy Market Report 2025 - Product Image

Spinal Muscular Atrophy Market Report 2025

  • Report
  • 175 Pages
  • Global
From

About the Spinal Muscular Atrophy Drug Market

Spinal Muscular Atrophy (SMA) is a rare genetic disorder that affects the motor neurons in the spinal cord, leading to progressive muscle weakness and wasting. As a result, individuals with SMA experience difficulty with activities of daily living, such as walking, eating, and breathing. Treatment for SMA is focused on managing symptoms and slowing the progression of the disease. The SMA drug market is a subset of the Central Nervous System (CNS) drug market. CNS drugs are used to treat a variety of neurological disorders, including SMA. Currently, there are several drugs approved for the treatment of SMA, including Spinraza, Zolgensma, and Evrysdi. These drugs are designed to slow the progression of the disease and improve the quality of life for those affected. Some of the companies in the SMA drug market include Biogen, Novartis, AveXis, and Roche. These companies are actively researching and developing new treatments for SMA, as well as providing access to existing treatments. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.